UBS upgraded Afya from Neutral to Buy
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/16/2026 | $16.00 | Buy → Neutral | UBS |
| 1/7/2026 | $22.00 | Overweight → Neutral | Analyst |
| 9/8/2025 | $24.50 | Neutral → Overweight | Analyst |
| 9/8/2025 | $19.00 | Neutral → Buy | UBS |
| 8/6/2025 | $17.50 | Underweight → Overweight | Morgan Stanley |
| 7/29/2025 | $14.00 | Sell → Neutral | Citigroup |
| 3/11/2025 | $19.00 → $17.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/31/2025 | $18.00 → $15.00 | Neutral → Sell | Citigroup |
UBS downgraded Afya from Buy to Neutral and set a new price target of $16.00
Analyst downgraded Afya from Overweight to Neutral and set a new price target of $22.00
Analyst upgraded Afya from Neutral to Overweight and set a new price target of $24.50
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and provider of medical practice solutions in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education ("MEC") has authorized an increase of 63 medical seats for ITPAC – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. ("Afya Abaetetuba"), located in the city of Abaetetuba, in the state of Pará. With this authorization, Afya's Abaetetuba campus will offer a total of 113 medical seats. As Afya Cametá—an approved but, non-operating medical school —and Afya Abaetetuba are located within the same health region, Afya
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today that Mrs. Maria Tereza Azevedo notified the Company of her intent to resign as a member of the Board of Directors of the Company, effective as of December 31, 2025. Afya thanks Maria Tereza for her dedication and meaningful contributions to the Board and wishes her continued success in her future endeavors. Afya's Board of Directors is composed of two co-chairmen - one representing Bertelsmann SE&Co. KGaA, and one representing the Esteves family -, one more member of the Esteves family, two more members of Bertelsmann SE&C
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
S-8 - Afya Ltd (0001771007) (Filer)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 Highlights 3Q25 Revenue increased 10.4% YoY to R$928.5 million. Revenue excluding acquisitions increased 10.1%, reaching R$926.2 million.
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highlights 2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million. 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to marke
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 9, 2025 was duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya's financial statements as of and for the fiscal year ended December 31, 2024; (2) the re-appointment of João Paulo Seibel de Faria as an independent director of the Company with immediate effect to hold office for a two year term; (3) the re-appointment of Vanessa Claro Lopes as an independent director of the Company with immediate effect to hold office for a two year term; (4) the re-appointment of Miguel Filisbino Pereira de Paula as an independent di
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make